Navigation Links
China Biologic Reports Financial Results for the Second Quarter and First Half of 2012
Date:8/9/2012

products remained the largest two sales contributors.

  • As a percentage of total sales, human albumin product revenue decreased to 38.7% in the second quarter of 2012 from 51.3% in the same quarter of 2011. During the three months ended June 30, 2012, sales volume of human albumin products declined by 18.4%, mainly due to decreased production volumes resulting from reduced raw material supply brought on by the closure of several plasma collection stations in Guizhou in 2011.
  • As a percentage of total sales, IVIG revenue increased to 42.1% in the second quarter of 2012 from 38.6% in the same quarter of 2011. Sales volume of IVIG products increased by 15.2% in the reporting quarter, mainly due to the increased production volume and access to higher inventory levels built up in the later part of 2011 in anticipation of the seasonal demand associated with Hand-Foot-and-Mouth Disease outbreaks.
  • Cost of sales increased by 28.9% to $16.1 million in the second quarter of 2012, from $12.5 million in the same quarter of 2011. Cost of sales as a percentage of total sales was 32.0%, slightly up from 30.0% in the same quarter of 2011. Volume and percentage increases in cost of sales were mainly due to increased sales activities and higher compensation paid to plasma donors, which brought the company's donor compensation amounts in line with the industry norm and helped the Company expand its plasma collection volume and donor base.

    Gross profit increased by 17.8% to $34.3 million in the second quarter of 2012, from $29.2 million in the same quarter of 2011. Gross margin decreased slightly to 68.0% from 70.0% in the second quarter of 2011, due to the increase in raw material costs.

    Total operating expenses in the second quarter of 2012 increased by 9.3% to $13.0 million from $11.9 million in the same quarter of 2011, primarily attributable to a 37.1% increase in selling expenses, which was partly offset by a 23.7% decrease in research and
    '/>"/>

    SOURCE China Biologic Products, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

    Related biology technology :

    1. China Cord Blood Corporation Files its Annual Report on Form 20-F
    2. In Vitro Diagnostics (IVD) - Emerging Countries (Brazil, Russia, India, China) Opportunity Assessment, Competitive Landscape and Market Forecasts to 2018
    3. Pressure BioSciences, Inc. Continues Global Sales Reach Expansion with Distribution Agreements for China, Vietnam, Laos, Cambodia, Australia, and New Zealand
    4. China Cord Blood Corporation Continues Share Repurchase Program
    5. Journal of Renewable and Sustainable Energy highlights energy trends in China
    6. WuXi PharmaTech Named a Top Ten Outsourcing Enterprise in China for Five Consecutive Years
    7. Sinovac to Present at 55th Annual BioPharma China Convention 2012 - Vaccine & Antibody Focus
    8. China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2012
    9. China Integrated Energy Inc. Completes Independent Investigation
    10. China Biologic Products Names Chairman David Gao to Additional Post of CEO
    11. China Pharma Holdings, Inc. to Report First Quarter of Fiscal Year 2012 Financial Results on May 15, 2012
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/21/2013)... Wisc. (PRWEB) May 21, 2013 ... parts distributor , will be exhibiting for the ... Advancement of Medical Instrumentation (AAMI) 2013 Conference and ... purchase, support, distribute, and manufacture healthcare technologies. This ... in Long Beach, California. , The three-day ...
    (Date:5/21/2013)... NC (PRWEB) May 21, 2013 ... financial services company for clinical trials, announced today ... Spend Solutions, LLC. Clinverse’s ClinPay® FLS eClinical ... investigator payment process. SpendMD ™, Aggregate ... complete solution for tracking and reporting transfer of ...
    (Date:5/21/2013)... Canada (PRWEB) May 21, 2013 ... is a strong push within the industry to ... and Manufacturing Organizations and pharma companies often means ... frames. , Microtablets, developed in collaboration with Sensidose ... effective outsourcing can bring products to market sooner. ...
    (Date:5/21/2013)... , May 21, 2013  MacroGenics, Inc. today ... of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody ... the HER2 oncoprotein," will be presented at the ... Clinical Oncology during the Developmental Therapeutics - Immunotherapy ... 4:15 – 4:30 PM.  The presentation will describe ...
    Breaking Biology Technology:Alpha Source, Inc. to Exhibit at the AAMI 2013 Conference and Expo 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
    ... 4, 2011 Palatin Technologies, Inc. (NYSE Amex: ... Phase 1 clinical trial of AZD2820, a subcutaneously-administered peptide ... therapy for the treatment of obesity. AZD2820 is a ... program with Palatin Technologies. Obesity is a ...
    ... SynCo Bio Partners B.V., one of the leading ... filling facility is again fully operational and SynCo has produced ... after the expansion of its Class A zone.   ... important milestone in SynCo,s strategy in supporting its clients with ...
    ...   Creabilis SA, a clinical stage ... and pain, announces today that Dr David Roblin has been ... extensive experience in the pharmaceutical industry in a career spanning ... several drugs to the market. He has held leadership roles ...
    Cached Biology Technology:Palatin Announces Commencement of a Phase 1 Trial for Obesity Compound in Collaboration with AstraZeneca 2Palatin Announces Commencement of a Phase 1 Trial for Obesity Compound in Collaboration with AstraZeneca 3SynCo Bio Partners Expands the Class A Zone in its Aseptic Filling Facility 2Creabilis Appoints Dr David Roblin as Chief Medical Officer 2Creabilis Appoints Dr David Roblin as Chief Medical Officer 3
    (Date:5/21/2013)... occur in the body, stem cells in the ... differentiating into mature immune cells that can fight ... deplete these cell populations, potentially leading to the ... Now, a team of researchers led by biologists ... found that, in mouse models, the molecule microRNA-146a ...
    (Date:5/21/2013)... University researchers have developed a new method for ... holes in the cell surface. The technique could ... related biological fields. , Bulk electroporation a ... reversible nanopores in the cell membrane that are ... is an increasingly popular method of cell transfection. ...
    (Date:5/21/2013)... new University of Michigan Water Center today awarded ... Great Lakes restoration and protection efforts. , The ... diverse projects, including efforts to track the remediation ... techniques to control non-native weedy plant invasions; study ... fish responses to restoration activities. , The grants ...
    Breaking Biology News(10 mins):Keeping stem cells strong 2Single-cell transfection tool enables added control for biological studies 2U-M Water Center awards $570K in Great Lakes restoration grants 2U-M Water Center awards $570K in Great Lakes restoration grants 3U-M Water Center awards $570K in Great Lakes restoration grants 4
    ... The Potato Genome Sequencing Consortium (PGSC), an international ... countries, has released a draft sequence of the potato ... Richard Veilleux, professor of horticulture in the College ... a unique phureja type of potato variety that accelerated ...
    ... could enhance plants, seed oil content for food and ... Science under an exclusive commercial agreement with Michigan State ... that regulates oil accumulation in plant seed was licensed ... technology transfer office. The gene is a transcription factor ...
    ... German . , Necessity is the mother ... harsh conditions of snow cover. This remarkable newly-acquired behaviour was ... in Seewiesen and their colleagues in a cave in Hungary. ... it and showed little or no interest in flying into ...
    Cached Biology News:Draft potato genome based on unique potato variety 2MSU licenses plant oil enhancement technology to BASF Plant Science 2Great tits eat bats in times of need 2